



用心玮护生命健康
CHERISH HEALTH OF LIFE WITH HEARTCARE

6609.HK

HEARTCARE

2022 INTERIM RESULT

AUG.2022



DISCLAIMER

NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAWS.

By attending this presentation or by reading this document, you (1) agree to be bound by these terms and (2) acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Group and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Group.

This document has been prepared regarding the company mentioned above in this document (the "Company") and its subsidiaries (together, the "Group") solely for use to introduce the Company and not for any other purpose, commercial, disclosure or otherwise.

This document contains confidential and proprietary information. The content of this document has not been independently verified. Certain factual statements and forecasts in this document are derived from external sources and have not been verified by the Company, any member of the Group, any of their respective affiliates, or any controlling persons, directors, officers, employees, agents, advisors or representatives of any of the foregoing.

No express or implied representation, warranty or undertaking is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. None of the Company, members of the Group, the Relevant Parties, their respective affiliates, or the controlling persons, directors, officers, employees, agents, advisors or representatives of any of the foregoing shall have any liability (due to negligence or any other reasons) for any loss howsoever arising from any information contained or presented in this document or otherwise arising in connection with this document. The information contained herein, the accuracy of which is not guaranteed, is provided as at the date of this document and is subject to change without notice, and will not be updated or otherwise revised to reflect any developments which may occur after the date of this document.

This document contains forward-looking statements that reflect the Company's current beliefs and expectations about the future as of the respective dates indicated herein. These statements contain the words "anticipate", "believe", "intend", "estimate", "expect" and words of similar meaning. All statements other than statements of historical facts included in this document, including, without limitation, those regarding the Chinese economy, the development trends of medical device industry and the Company's future financial position, results of operations, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Company's products and services) are forward-looking statements. These forward-looking statements are based on a number of assumptions which are subject to known and unknown risks, uncertainties and other factors that are beyond the Company's control, such as the political, social, legal and economic environment in which the Company will operate in the future, which could cause the actual results and performance of the Company to differ materially from the results and performance expressed or implied in such forward-looking statements. These forward-looking statements reflect the view of the Company's management as of the date of this document only and are not a guarantee of future performance. Accordingly, no reliance should be placed excessively on these statements. None of the Company, members of the Group, the Relevant Parties, their respective affiliates, or the controlling persons, directors, officers, employees, agents, advisors or representatives of any of the foregoing assumes any obligation to update or otherwise revise these forward-looking statements for new information, events or circumstances that occur subsequent to such dates or otherwise, and each of the Company, members of the Group and Relevant Parties expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein.

This document and presentation contain information sourced from, and the views of, independent third parties. In replicating such information, none of the Company, members of the Group, the Relevant Parties, their respective affiliates, or any controlling persons, directors, officers, employees, agents, representatives or advisors of any of the foregoing makes any representation as to its accuracy or assumes any responsibility thereof. The replication of such views or information should not be treated as indication that the Company or the Relevant Parties agree or concur with such views or information.

This document and any oral information provided in connection with it do not constitute or form part of, and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company or any of its shareholders, subsidiaries or affiliates in any jurisdiction or an inducement to enter into investment activity. No money, securities or any other consideration is being solicited. No part of this document, nor the fact of its distribution, shall form the basis of or be relied upon in connection with any contract, commitment or investment decision whatsoever. The information contained herein is not (a) an offering to you or the public of the shares or securities of the Company for purchase for cash or other consideration; or (b) circulated to invite offers by you or the public to purchase for cash or other consideration any securities of the Company.

This document is not for distribution, nor does it constitute an offer to sell or solicitation to purchase or subscribe for securities, in the United States or any other jurisdictions or to a U.S. person. Neither the document nor any copy of it may be taken, distributed or transmitted into the United States or its territories or possessions or distributed, directly or indirectly, in the United States or its territories or possessions or to any U.S. person. Any failure to comply with this restriction may constitute a violation of U.S. securities laws.

By attending this presentation or reading this document, you will be deemed to acknowledge receipt of material non-public information about the Company and the Group, and you will be deemed to consent and agree that (i) you shall be bound by the restrictions as set forth in this document and to maintain absolute confidentiality regarding any information disclosed (whether written or verbal), and you shall indemnify and keep indemnified the Company, members of the Group, the Relevant Parties, their respective affiliates, and the controlling persons, directors, officers, employees, agents, advisors and representatives of each of the foregoing against all losses, damages, expenses and costs that any of them may sustain or incur as a result, whether directly or indirectly, of any breach of any provision in this disclaimer by you; (ii) any use of the information in this document by you other than in accordance with applicable law and stock exchange rules may constitute a violation of applicable laws, rules or regulations, including in relation to insider dealing/trading; and (iii) you are solely responsible for any consequences arising from any such violation. The distribution of the information in this document in other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions.

Neither the delivery of this document nor any further discussions of the Company with any of the recipients of this document shall, under any circumstances, create any implication that there has been no change in the affairs of the Company or the Group since such date.

*This disclaimer should be construed in accordance with the laws of Hong Kong.

Improve the accessibility of innovative medical technologies



▶ HeartCare Medical

(stock code: 06609.HK)




Our vision is to improve the accessibility of innovative medical devices and protecting lives and health.



In the field of neuro-intervention, we provide **First and Only domestic one-stop solution for stroke treatment and prevention.**

2022 Interim Results Overview

Net loss Narrowed by strong growth in revenue, R&D spending increased



6
New products approved



15
Commercialized neuro-interventional product pipeline



2
NMPA Priority review of innovative medical devices



National Level
Specialized and Novel Enterprise

2022 Interim Results Overview

Creating competitive domestic brand image

Improving Brand Competitiveness

01

Distribution Network Advantage

- ✓ Extensive channel coverage, catching opportunity in rapidly-growing primary market
- ✓ Accelerating market access
- ✓ Stabilized sales network, ensuring product supply

02

Product Portfolio Advantage

- ✓ A complete product portfolio, covering all kinds of neuro-interventional procures
- ✓ Cutting-edge product innovations, achieving higher competitiveness
- ✓ “Star Product” to promote solid brand image

03

Supply Chain Advantage


- ✓ Stable quality
- ✓ Sufficient supply
- ✓ Cost-effective and sustainable

Neuro-intervention Performance Review


Product portfolio advantage

☰ NMPA-approvals


Acute ischemic stroke (AIS) treatment




Intracranial aspiration catheter




Intracranial thrombectomy stent




Distal access catheter



Aspiration pump




Balloon guiding catheter




Microcatheter


Neurovascular stenosis treatment



Carotid artery balloon dilatation catheter




Intracranial balloon dilatation catheter




Embolization protection system

Hemorrhagic stroke treatment



Emboloc coiling system

Prevention of AIS



Left atrial appendage occluder

Endovascular access devices



Vascular closure device



Neuro-interventional micro guidewire



Support catheter



Neuro-interventional microcatheter

☐ Updating

Product name	Design	Clinical trial	Registra-tion	NMPA Approval
Distal access catheter II				
Intracranial thrombectomy stent II				
Aspiration catheter II				
Intracranial balloon dilatation catheter II				

Neuro-intervention Performance Review


Product portfolio advantage

Intracranial DEB




- ✓ Expected to be the 1st rapamycin drug-eluting balloon for the treatment of neurovascular stenosis to get approval worldwide
- ✓ Clinical trial completed, prepared for NMPA registration
- ✓ NMPA Green Channel

Embolization assisting stent



- ✓ Expected to be the 1st domestic intracranial embolization assisting stent to get approval
- ✓ Clinical trial in process
- ✓ NMPA Green Channel

Flow diverter



- ✓ Expected to be the 1st domestic newly drug-coating mesh stent to get approval
- ✓ Clinical trial in process

Neuro-intervention Performance Review

Sale channel advantage

Sales Channel



100+

In-house sales



100+

Distributors



31


Provinces and
autonomous regions



~1,000

Hospitals

Branding



Neuro-intervention Performance Review

Supply chain advantage



Nanjing Jiangbei New District



Shanghai Zhangjiang



Shanghai Lingang



Shanghai Lingang (CIP)



Qualification rate for new products are improving



Stabilized supply chain with sufficient raw material reservation



Sustainable construction of capacity



Nearly 10,000 m²
Manufacturing facility

Future and Outlook

Business plan with sustainable competitiveness


01



Neuro-intervention

Branding and Growing
Market Share

02



Cardiac Intervention

Pipeline Products
R&D and Commercialization

03




Emerging Business

Innovative
Technology and Device

Future and Outlook


Highly- effective R&D platform for unmet clinical needs



- Commercialized: **LAAO**
- To be approved in 2024: **Cryoablation**
- To be approved in 2025 : **PFA,TEER**



30+
Product candidates



- To be approved in 2023-2024 : **Aspirational thrombectomy, Thrombectomy stent & balloons**
- To be approved in 2025 : **Ablation equipment & devices**



200+
Patent application




- To be approved in 2024 : **Cardiovascular intervention robots**
- To be approved in 2025 : **Neurosurgery navigation systems, Endovascular robotics II**




100+
R&D engineers

Company Overview


Cardiac intervention: a complete innovative medical solution




AF Treatment & Stroke Prevention




Heart Failure



Mitral/Tricuspid Regurgitation/Stenosis



Cardiovascular Intervention Robotics





THANKS

AUG.2022

